1 / 29

What are the risks and benefits of Tyrosine Kinase I nhibitors ?

What are the risks and benefits of Tyrosine Kinase I nhibitors ?. Wendy Osborne Consultant Haematologist Freeman Hospital, Newcastle. Outline of presentation. Discuss common side effects Risk benefit decisions of choice of drug Strategies to reduce side effects. Pre- imatinib era.

kelly-caldwell
Download Presentation

What are the risks and benefits of Tyrosine Kinase I nhibitors ?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. What are the risks and benefits of Tyrosine Kinase Inhibitors ? Wendy Osborne Consultant Haematologist Freeman Hospital, Newcastle

  2. Outline of presentation • Discuss common side effects • Risk benefit decisions of choice of drug • Strategies to reduce side effects

  3. Pre-imatinib era

  4. Current Tyrosine kinase inhibitors • Imatinib • Nilotinib • Dasatinib • Bosutinib • Ponatinib

  5. Imatinib is a safe drug…Iris 8 year follow up All grade AE Grade 3/4 AE Oedema 60% 2% Nausea 50% 1% Cramps 49% 2% Diarrhoea 45% 3% Rash/skin 40% 3% Fatigue 39% 2% Headache 37% <1% Abdo pain 37% 4% Joint pain 31% 3%

  6. Rashes

  7. Periorbital oedema

  8. Monitoring of liver function

  9. What else have we learned from IRIS? Grade 3/4 adverse events decreased in incidence after years 1 and 2 With >400 000 patient years of estimated imatinib exposure there is no evidence that imatinib increases risk of other malignancies.

  10. Nilotinib • Enestnd follow up suggests that it is better tolerated than imatinib , but…. • Concerns about cardiovascular risk

  11. Is Dasatinibany better?

  12. Pleural effusion

  13. Pleural effusion • 20% incidence (SPIRIT 2 and Dasision) • More common with higher doses/split doses dasatinib • Most occur within 12 months

  14. Pulmonary arterial hypertension • Estimated incidence 0.45% • Late complication, 8-48 months after starting • Reversible

  15. Bosutinib • Bosutinib: GI side effects • 84% Diarrhoea • 44% Nausea • 35% vomiting Start with low dose and build up. Warn patients and give loperimide

  16. Ponatinib • Available for patients with T315I mutation • Effective drug but …

  17. PACE - Incidence of Vascular Events

  18. Evaluation of PonatinibvsImatinib in CML: EPIC • Phase 3, randomized, open-label trial of oral ponatinib vs. oral imatinib in patients with newly diagnosed CP-CML

  19. Vascular occlusive events EPIC was terminated October 2013. Safety concerns/achieving endpoints if dose change. Ponatinib not to be used first line.

  20. FDA approval for ponatinib • Treatment of adult patients with T3151-positive chronic myeloid leukaemia or Ph+ ALL • Patients in whom no other TKI is indicated • label to describe the vascular occlusion events.

  21. EMA decision re ponatinib • Not to be used in patients with a history of heart attack or stroke, unless the potential benefits of treatment outweigh the risks. • Cardiovascular risk factors actively managed. • Patients should be monitored for evidence of vascular occlusion or thromboembolism. • Review 10/10/14: stop if no response 3 months

  22. Risk reduction • Assess cardiovascular risk factors

  23. Modifications if side effects • Reduce the dose of drug • Dose interruptions • Alternative TKI • Address risk factors

  24. Conclusions • All drugs have side effects. • Risk benefit of disease control verses side effect profile. • Reduction of cardiovascular risk factors • More patients are interested in reducing dose or stopping TKI

More Related